New hope for tough leukemia: drug combo trial launches

NCT ID NCT07508982

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of two drugs, azacitidine (a standard chemotherapy) and APG1252 (a new targeted therapy), in people with high-risk acute myeloid leukemia (AML). The goal is to see if the combo is safe and can help control the disease. About 52 participants will be enrolled, including those whose cancer has returned or not responded to prior treatment, as well as some newly diagnosed patients with specific AML subtypes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Azacitidine and APG1252 (Pelcitoclax)
What this could lead to: If this works, it could offer a new treatment option for people with hard-to-treat AML, potentially improving remission rates.
What could go wrong: This is an early-phase trial with only 52 participants, so results are uncertain. The drug combo may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML

Contacts and locations

Locations

UT MD Anderson
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.